Home Labs

What Is Multi-Cancer Early Detection (MCED) Testing? Galleri and Similar Tests Explained

By Darrin LaVelle, Founder of RENVA Health

Last updated: August 24, 2026

3 min read

Short answer: multi-cancer early detection (MCED) — also called multi-cancer detection (MCD) — blood tests look for molecular signals such as cell-free DNA methylation patterns that may suggest cancer is present. They are not FDA-approved; some (including Galleri) are available as lab-developed tests under CLIA. They do not diagnose cancer, must not replace proven screenings like mammography or colonoscopy, and a positive signal always needs diagnostic follow-up.

Marketing for these tests often emphasizes finding cancers that lack routine screening. The clinical and regulatory picture is still evolving — and the American Cancer Society is explicit that there are not yet U.S. clinical practice guidelines recommending them for general screening.[1]

How MCED / MCD Blood Tests Work

MCD tests analyze blood or other fluids for pieces of DNA, RNA, or proteins associated with abnormal cells.[1] One commercially available approach (Galleri) uses targeted methylation sequencing of circulating cell-free DNA and machine-learning classifiers to report a cancer signal and, when possible, a predicted tissue of origin to guide workup.[2] A positive result is a signal — not a tumor diagnosis, stage, or treatment plan.

Regulatory Status: Not FDA-Approved

ACS states that MCD tests have not been cleared or approved by the FDA; some are offered as lab-developed tests under CLIA, which allows clinicians to order them.[1] ASCO's Educational Book likewise notes that no MCED has FDA approval for multi-cancer screening, while Galleri is commercially available through the CLIA pathway ahead of definitive randomized-outcome evidence.[2] Availability is not the same thing as guideline-endorsed population screening.

Key limit: MCED tests should not replace recommended screenings for breast, cervical, colorectal, lung, and prostate cancers.[1][3]

What Guidelines and Experts Say Today

ACS reports that there are currently no clinical practice guidelines or official U.S. recommendations for using MCDs, and encourages shared decision-making that covers benefits, limits, harms, and uncertainties.[1] Proven ACS screening pathways — mammograms, colorectal screening starting at average-risk age 45, cervical screening, LDCT for eligible high-risk smokers, and informed PSA discussions — remain the evidence-based backbone.[3] ASCO authors emphasize that commercial availability has outpaced randomized evidence that MCED testing improves cancer outcomes.[2]

Positive Signals, False Positives, and False Negatives

MCD tests do not diagnose cancer. A positive result requires additional testing to confirm whether cancer is present, what type, and where.[1] ACS notes that research so far shows over half of people with positive MCD results do not have cancer on further evaluation — false positives that can drive anxiety and unnecessary procedures.[1] False negatives can create false reassurance; a negative MCED result does not replace scheduled guideline screenings or evaluation of new symptoms.[1]

Who Should Consider a Conversation — Not a DIY Diagnosis

If you are considering Galleri or a similar test, talk with a clinician about cost (often out-of-pocket), willingness to pursue diagnostic workup after a positive signal, and how the test would sit alongside — never instead of — mammography, colonoscopy/stool-based colorectal screening, cervical screening, and other indicated tests.[1][3] Treat MCED as an emerging adjunct under active study, not a one-blood-draw replacement for cancer screening medicine.

Sources

  1. Multi-cancer Detection (MCD) Tests American Cancer Society cancer.org
  2. Multicancer Early Detection Tests at a Crossroads: Commercial Availability Ahead of Definitive Evidence ASCO Educational Book ascopubs.org
  3. American Cancer Society Guidelines for the Early Detection of Cancer American Cancer Society cancer.org

Frequently Asked Questions

Is the Galleri test FDA-approved?

No. ACS and ASCO both state that MCED/MCD tests are not FDA-approved; Galleri is available as a lab-developed test under CLIA.[1][2]

Can MCED replace my mammogram or colonoscopy?

No. ACS is clear that MCD tests should not replace recommended screenings such as mammograms and colorectal screening exams or stool tests.[1][3]

What happens if my MCED test is positive?

You need diagnostic follow-up with a clinician. A positive MCED result is not a cancer diagnosis, and false positives are common enough that ACS highlights them as a major uncertainty.[1]

Medical disclaimer: RENVA is not a healthcare provider. This article is informational and educational only. It does not constitute medical advice, diagnosis, or a prescription. Always consult a licensed healthcare professional before making health decisions. Full medical disclaimer →

Provider Match Quiz

Find providers worth comparing.

Answer a few preference questions — budget, labs, provider model, and cancellation flexibility. Preference-based and informational only.

Take the free quiz
Related comparisons